



January 28, 2015
Announcement no. 2

Market rumours about rejection of NGAL cut-off patent application

Today BioPorto became aware of market rumours that the company's divisional cut-off patent application no. EP2128625 has been rejected by the European Patent Office (EPO).

These rumours are not true. As part of the normal patent application processing, the EPO has submitted a so-called "Office Action" to BioPorto, requesting further clarification of a number of circumstances relating to BioPorto's divisional NGAL cut-off patent application.

Accordingly, the application process concerning the divisional NGAL cut-off patent will continue according to standard EPO procedures.

Further details from:

Peter Mørch Eriksen, CEO
Phone 45 29 00 00, mail investor@bioporto.com

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX Copenhagen stock exchange.